News•Mar 26, 2026
Reclaiming the Narrative: What BioPharma Must Learn From Tech Before It's Too Late
Tech talent and capital are rapidly flowing into biotech as AI makes traditional software a commodity. Executives like Bezos and Altman are funding anti‑aging ventures, while firms such as Nvidia and Google explore drug‑related R&D. The article argues that biotech must adopt tech’s risk appetite, platform thinking, and storytelling while preserving rigorous scientific standards. Without a balanced approach, the industry risks both missed opportunities and reputational damage.
By Big Pharma Sharma
Podcast•Feb 26, 2026•0 min
Drug Dealin Ep. 9: Using AI to Find Novel Treatment Options
In Episode 9 of Drug Dealin, hosts Kenny and Shibu demonstrate how patients can use publicly available tools like ClinicalTrials.gov and AI language models to uncover novel treatment options, focusing on a hypothetical Parkinson’s disease case inspired by a TV...
By Big Pharma Sharma